GAITHERSBURG, Md. — August 11, 2025 — Leads & Copy — Altimmune, Inc. (Nasdaq: ALT) has announced the appointment of Jerry Durso as Chairman of the Board, effective August 12, 2025. Durso succeeds Mitchel Sayare, Ph.D., who will remain on the Board as an Independent Director.
The transition aligns with the company’s plans to advance pemvidutide into Phase 3 development for metabolic dysfunction-associated steatohepatitis (MASH). Altimmune anticipates an End-of-Phase 2 Meeting with the FDA for MASH in Q4 2025.
Vipin K. Garg, Ph.D., President and CEO of Altimmune, expressed gratitude to Sayare for his leadership and welcomed Durso to his new role.
Durso brings over 30 years of experience in the life sciences industry, most recently serving as CEO of Intercept Pharmaceuticals. He holds a BBA in marketing from the University of Notre Dame.
Greg Weaver, Chief Financial Officer, 240-654-1450, ir@altimmune.com
Source: Altimmune, Inc.
